Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP). Academic Article uri icon

Overview

abstract

  • Care of patients with chronic immune thrombocytopenia (ITP) who are refractory to available treatments can be quite challenging. Fostamatinib, an oral Syk inhibitor, is the newest FDA-approved agent for ITP. Phase 3 clinical trials demonstrated an overall response in 43% of patients treated with fostamatinib and use for two years has been reported. Herein, we report two patients with long histories of ITP without lasting responses to numerous first-, second- and third-line therapies with prolonged responses to ongoing fostamatinib. This shows that patients unresponsive to other agents may respond to fostamatinib and can have sustained benefit.

publication date

  • January 3, 2020

Research

keywords

  • Oxazines
  • Purpura, Thrombocytopenic, Idiopathic
  • Pyridines

Identity

Scopus Document Identifier

  • 85077888344

Digital Object Identifier (DOI)

  • 10.1111/bjh.16328

PubMed ID

  • 31900937

Additional Document Info

volume

  • 189

issue

  • 2